Enhancement of zaleplon oral bioavailability using optimized self-nano emulsifying drug delivery systems and its effect on sleep quality among a sample of psychiatric patients.
Acetamides
/ administration & dosage
Administration, Oral
Adult
Biological Availability
Cross-Sectional Studies
Drug Carriers
/ chemistry
Emulsions
Female
Humans
Hypnotics and Sedatives
/ administration & dosage
Male
Mental Disorders
/ blood
Middle Aged
Nanoparticles
/ chemistry
Pyrimidines
/ administration & dosage
Sleep Initiation and Maintenance Disorders
/ blood
Solubility
Young Adult
Zaleplon
bioavailability
poorly water-soluble drug and quality of sleep
self-nano emulsifying drug delivery system (SNEDDS)
Journal
Drug delivery
ISSN: 1521-0464
Titre abrégé: Drug Deliv
Pays: England
ID NLM: 9417471
Informations de publication
Date de publication:
Dec 2019
Dec 2019
Historique:
entrez:
23
11
2019
pubmed:
23
11
2019
medline:
21
4
2020
Statut:
ppublish
Résumé
The aim of this work is to develop self-nano emulsifying drug delivery system (SNEDDS) to enhance the oral bioavailability of zaleplon (Zal) as a poorly water-soluble drug. Moreover, the bioavailability and the effect on the quality of sleep among a sample of psychiatric patients is to be assessed. D-optimal mixture design was used for optimization. Optimized SNEDDS formulation was evaluated for droplet size, transmission electron microscope (TEM) and in-vitro dissolution test. Zal bioavailability was evaluated by determining its serum concentration and pharmacokinetic parameters in 8 patients after oral administration. Effect on sleep quality was assessed among 40 psychiatric patients. Patients' sleep quality was assessed in 40 psychiatric patients before and after medication using the Arabic version of the Pittsburgh Sleep Quality Index (PSQI). Zal- SNEDDS appeared as nano-sized spherical vesicles. Moreover, Zal was completely dissolved from optimized formulation after 45 min indicating improved dissolution rate. Zal-SNEDDS showed significantly higher
Identifiants
pubmed: 31752566
doi: 10.1080/10717544.2019.1687613
pmc: PMC6882476
doi:
Substances chimiques
Acetamides
0
Drug Carriers
0
Emulsions
0
Hypnotics and Sedatives
0
Pyrimidines
0
zaleplon
S62U433RMH
Types de publication
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
1243-1253Références
Expert Opin Drug Deliv. 2014 Jul;11(7):1005-13
pubmed: 24702435
Psychiatry Res. 1989 May;28(2):193-213
pubmed: 2748771
Drug Deliv. 2015;22(4):522-30
pubmed: 24512464
Nephron Clin Pract. 2003;94(4):c99-103
pubmed: 12972720
Psychiatry Res. 2000 Dec 27;97(2-3):165-72
pubmed: 11166088
AAPS PharmSciTech. 2009;10(1):172-82
pubmed: 19224372
Nanomedicine (Lond). 2010 Dec;5(10):1595-616
pubmed: 21143036
Chang Gung Med J. 2011 Jan-Feb;34(1):50-6
pubmed: 21392474
J Young Pharm. 2011 Jan;3(1):4-8
pubmed: 21607048
Spectrochim Acta A Mol Biomol Spectrosc. 2007 Dec 31;68(5):1220-30
pubmed: 17353143
Pharmaceutics. 2016 Jun 27;8(3):
pubmed: 27355963
AAPS PharmSciTech. 2015 Feb;16(1):53-8
pubmed: 25168449
Afr Health Sci. 2013 Jun;13(2):369-75
pubmed: 24235938
Nanomedicine. 2012 Sep;8 Suppl 1:S5-20
pubmed: 22846372
AAPS PharmSciTech. 2012 Sep;13(3):967-77
pubmed: 22760454
AAPS PharmSciTech. 2018 Apr;19(3):1358-1366
pubmed: 29352403
Front Psychiatry. 2019 May 09;10:284
pubmed: 31143131
J Microencapsul. 2013;30(2):161-72
pubmed: 22894164
Prog Lipid Res. 2017 Oct;68:1-11
pubmed: 28778472
Int J Pharm. 2008 May 1;355(1-2):269-76
pubmed: 18242895
ISRN Pharm. 2013 Dec 26;2013:848043
pubmed: 24459591
J Med Toxicol. 2013 Jun;9(2):163-71
pubmed: 23456542
Neurol Clin. 2012 Nov;30(4):1389-413
pubmed: 23099143
Curr Drug Deliv. 2018;15(6):898-906
pubmed: 29189154
Drug Deliv. 2011 Nov;18(8):599-612
pubmed: 22008038
AAPS PharmSciTech. 2008;9(2):536-43
pubmed: 18431649
Sleep Sci. 2016 Jul-Sep;9(3):202-206
pubmed: 28123661
Clin Pharmacokinet. 2004;43(4):227-38
pubmed: 15005637
J Control Release. 2002 May 17;81(1-2):65-74
pubmed: 11992679
Int J Geriatr Psychiatry. 2000 Aug;15(8):704-12
pubmed: 10960882